Early Detection of Tumor Relapse in Triple Negative Breast Cancer
Abstract
In the 2nd annual progress report, we report the following results: Firstly, we identified the corresponding tumor blocks pre- and post-NACT for the automatic IHC staining, clinical histology, and pathology analysis of a valuable cohort of 577 TNBC patients who have a natural partition of 50 African Americans (AA) and 50 Caucasian patients at stage 2-3-4 from Hampton Roads Virginia. In this cohort, AA TNBC patients have a high incidence rate of TNBC. KM survival curves showed that our local stage III-IV TNBC patients have a much reduced survival rate as compared to that of the national average of stage III-IV TNBC survival using the SEER database, indicative of a pressing need to identify chemo-resistant residual tumors, detect cancer disparities, forecast early tumor relapse, and predict patient survival in our local TNBC cohort as early as possible (Figures 3 4, and Table 1). Secondly, we reported that SIAH is a reliable prognostic biomarker in predicting patient survival in a 10-year study in NACT-treated high-risk breast cancer patients (Figures 5 - 8). Thirdly, we conducted reverse phase protein array (RPPA)-based kinomic analysis to delineate how the major cancer signaling pathways and network are rewired in response to anti-SIAH2 targeted therapy in TNBC cells lines (Figures 10 - 15). Due to the COVID-19 social distance restrictions at Sentara Hospitals, we have encountered repeated delays in carrying out the IHC staining of this TNBC project. With the state of Virginia re-opening on May 28, 2021, we are expected to catch up on this project rapidly.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2021
- Accession Number
- AD1145065
Entities
People
- Amy H Tang
Organizations
- Eastern Virginia Medical School